Gland Pharma Limited (BOM:543245)
India flag India · Delayed Price · Currency is INR
1,886.60
-41.65 (-2.16%)
At close: Aug 28, 2025

Gland Pharma Ratios and Metrics

Millions INR. Fiscal year is Apr - Mar.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 20212018 - 2021
Period Ending
Aug '25 Mar '25 Mar '24 Mar '23 Mar '22 Mar '21 2018 - 2021
308,342262,358303,932208,882537,705405,432
Upgrade
Market Cap Growth
0.48%-13.68%45.50%-61.15%32.63%-
Upgrade
Enterprise Value
281,957237,423286,055175,977508,469390,204
Upgrade
Last Close Price
1867.001577.511806.281244.073205.932429.88
Upgrade
PE Ratio
40.0337.5639.3526.7444.3840.67
Upgrade
PS Ratio
5.394.675.375.7612.2211.71
Upgrade
PB Ratio
3.372.873.482.637.516.87
Upgrade
P/TBV Ratio
3.512.983.632.637.536.87
Upgrade
P/FCF Ratio
-49.4850.08146.03192.42107.78
Upgrade
P/OCF Ratio
-28.6830.4957.3968.0067.02
Upgrade
EV/Sales Ratio
4.934.235.054.8611.5511.27
Upgrade
EV/EBITDA Ratio
20.8419.2822.0617.0733.6729.97
Upgrade
EV/EBIT Ratio
29.1827.2229.4519.9036.3232.42
Upgrade
EV/FCF Ratio
-44.7847.14123.03181.96103.74
Upgrade
Debt / Equity Ratio
0.030.030.040.000.000.00
Upgrade
Debt / EBITDA Ratio
0.230.250.280.000.000.00
Upgrade
Debt / FCF Ratio
-0.590.610.030.020.01
Upgrade
Asset Turnover
-0.510.580.440.610.65
Upgrade
Inventory Turnover
-1.441.401.161.791.56
Upgrade
Quick Ratio
-3.012.616.587.807.31
Upgrade
Current Ratio
-4.344.049.4610.0610.00
Upgrade
Return on Equity (ROE)
-7.82%9.26%10.33%18.55%20.88%
Upgrade
Return on Assets (ROA)
-4.98%6.25%6.65%12.21%14.22%
Upgrade
Return on Capital (ROIC)
6.51%5.87%7.12%7.31%13.39%15.73%
Upgrade
Return on Capital Employed (ROCE)
-9.00%10.50%11.00%19.30%20.10%
Upgrade
Earnings Yield
2.50%2.66%2.54%3.74%2.25%2.46%
Upgrade
FCF Yield
-2.02%2.00%0.69%0.52%0.93%
Upgrade
Dividend Yield
0.95%1.14%1.11%---
Upgrade
Payout Ratio
-47.17%----
Upgrade
Buyback Yield / Dilution
-0.03%-0.01%-0.03%-0.09%-3.96%-2.15%
Upgrade
Total Shareholder Return
0.93%1.13%1.07%-0.09%-3.96%-2.15%
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.